The critical mass of biosimilars in the US is surely getting there. My opinion: now it’s time for price competition. Otherwise you have to ask, what was the point of it all? Maybe I’m just a naive foreigner. But US patients deserve better. #ACR23 @US_FDA session @RheumNow https://t.co/enHY6xffMa

#ACR23 IV secukinumab vs placebo at 52 Weeks @RheumNow https://t.co/4zQa37tN4l

Ab#498 Does DMARD for PsO and PsA decrease MACE? #ACR23 @RheumNow Retrospective database Israeli study. PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001) Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp

Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/vucBYeM1P5 https://t.co/YqdqZWFhfd

• Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analy…

Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

Higher disease activity and systemic inflammation at baseline associated with greater risk of MACE in bDMARD nonusers but not in users. bDMARD-specific benefits directly on MACE risk beyond reducing inflammation, Karpouzas et al Abst#0391 #ACR23 @RheumNow https://t.co/lfoccZffTW https://t.co/ASpKYQof1I

Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE OPTIMAL ➡️ tx-naive ➡️Phase III, 852 pts, bimekizumab, PBO, ADA ➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️Peresolimab ➡️ stimulates PD1 ➡️ Phase II, 98 pts ➡️ tx-resistant to other therapies including biologics ➡️ Wk 12: better DAS28, ACR20, not ACR 50/70 #ACR23 @RheumNow